An Introduction to Celestial Mechanics

Includes bibliography.Mode of access: Internet

The Written Description Requirement

It is now well accepted that this provision of the 1952 Patent Act (Patent Act) includes a written description requirement that is separate and distinct from the enablement requirement. Thus, a specification may enable one of ordinary skill to make or use a claimed invention, but still not adequately describe the invention in a way that the public knows that the inventor was in possession of the claimed invention at the time of filing the application. For example, a patent specification that discloses various patterns of eight wooden shingles, does not necessarily provide written description for a claim amendment that recites “at least six shingles,” even though the specification would enable one so inclined to construct a panel of at least six wooden shingles. However, it was not entirely clear from the language of the Patent Act itself that there was a written description requirement separate and distinct from the enablement requirement. The well-accepted understanding that these are separate and distinct requirements flows from judicial decisions, and not the text of the Patent Act itself

Prevalence and Risk-Factors of Publication Bias in German Sociology

Die statistische Signifikanz von Forschungsergebnissen wird oft fälschlicherweise als ein Indikator für deren Relevanz und Aussagekraft gehalten. Signifikante Ergebnisse werden eher veröffentlicht, obwohl nicht-signifikante Ergebnisse gleichermaßen für den Erkenntnisfortschritt bedeutsam sind. Die Folgen sind eine Überschätzung von Effektstärken und eine zu optimistische Beurteilung von Theorien. Im vorliegenden Beitrag wird dem Problem des Publication Bias (PB) in der deutschen Soziologie anhand von elf Jahrgängen der zwei wichtigsten deutschsprachigen Soziologie-Zeitschriften (Kölner Zeitschrift für Soziologie und Sozialpsychologie, Zeitschrift für Soziologie) mithilfe des Caliper-Tests nachgegangen. Lassen sich ebenso wie in US-amerikanischen Soziologie-Zeitschriften Hinweise auf einen PB finden, und wenn ja, unter welchen Bedingungen ist dieser besonders stark ausgeprägt? Im Mittelpunkt der Ursachenanalyse stehen Möglichkeiten der Datenmanipulation sowie der sozialen Kontrolle durch Forschende.Im Ergebnis finden sich auch für die deutsche Soziologie Hinweise auf einen PB, wenngleich in schwächerem Umfang als in US-amerikanischen Zeitschriften. Einfache Maßnahmen wie Herausgebervorgaben, wonach Daten für Replikationen zur Verfügung zu stellen sind, zeigen keine durchschlagende Wirkung. Es lässt sich lediglich eine leichte Tendenz feststellen, dass komplexe Arbeiten mit mehreren parallel zu testenden Hypothesen das PB-Risiko abmildern.publishe

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Background: The extent to which the prognosis for AIDS and death of patients initiating highly active antiretroviral therapy (HAART) continues to be affected by their characteristics at the time of initiation (baseline) is unclear. Methods: We analyzed data on 20,379 treatment-naive HIV-1- infected adults who started HAART in 1 of 12 cohort studies in Europe and North America (61,798 person-years of follow-up, 1844 AIDS events, and 1005 deaths). Results: Although baseline CD4 cell count became less prognostic with time, individuals with a baseline CD4 count 350 cells/μL (hazard ratio for AIDS = 2.3, 95% confidence interval [CI]: 1.0 to 2.3; mortality hazard ratio = 2.5, 95% CI: 1.2 to 5.5, 4 to 6 years after starting HAART). Rates of AIDS were persistently higher in individuals who had experienced an AIDS event before starting HAART. Individuals with presumed transmission by means of injection drug use experienced substantially higher rates of AIDS and death than other individuals throughout follow-up (AIDS hazard ratio = 1.6, 95% CI: 0.8 to 3.0; mortality hazard ratio = 3.5, 95% CI: 2.2 to 5.5, 4 to 6 years after starting HAART). Conclusions: Compared with other patient groups, injection drug users and patients with advanced immunodeficiency at baseline experience substantially increased rates of AIDS and death up to 6 years after starting HAART

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19 : a meta-analysis

IMPORTANCE Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm. OBJECTIVE To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes. DATA SOURCES Trials were identified through systematic searches of electronic databases between October 2020 and January 2021. Searches were not restricted by trial status or language. Additional trials were identified through contact with experts. STUDY SELECTION Eligible trials randomly assigned patients hospitalized for COVID-19 to a group in whom IL-6 antagonists were administered and to a group in whom neither IL-6 antagonists nor any other immunomodulators except corticosteroids were administered. Among 72 potentially eligible trials, 27 (37.5%) met study selection criteria. DATA EXTRACTION AND SYNTHESIS In this prospectivemeta-analysis, risk of biaswas assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I-2 statistic. The primary analysis was an inverse variance-weighted fixed-effects meta-analysis of odds ratios (ORs) for 28-day all-cause mortality. MAIN OUTCOMES AND MEASURES The primary outcome measurewas all-cause mortality at 28 days after randomization. There were 9 secondary outcomes including progression to invasive mechanical ventilation or death and risk of secondary infection by 28 days. RESULTS A total of 10 930 patients (median age, 61 years [range of medians, 52-68 years]; 3560 [33%] were women) participating in 27 trials were included. By 28 days, there were 1407 deaths among 6449 patients randomized to IL-6 antagonists and 1158 deaths among 4481 patients randomized to usual care or placebo (summary OR, 0.86 [95% CI, 0.79-0.95]; P =.003 based on a fixed-effects meta-analysis). This corresponds to an absolute mortality risk of 22% for IL-6 antagonists compared with an assumed mortality risk of 25% for usual care or placebo. The corresponding summary ORs were 0.83 (95% CI, 0.74-0.92; P <.001) for tocilizumab and 1.08 (95% CI, 0.86-1.36; P =.52) for sarilumab. The summary ORs for the association with mortality compared with usual care or placebo in those receiving corticosteroids were 0.77 (95% CI, 0.68-0.87) for tocilizumab and 0.92 (95% CI, 0.61-1.38) for sarilumab. The ORs for the association with progression to invasive mechanical ventilation or death, compared with usual care or placebo, were 0.77 (95% CI, 0.70-0.85) for all IL-6 antagonists, 0.74 (95% CI, 0.66-0.82) for tocilizumab, and 1.00 (95% CI, 0.74-1.34) for sarilumab. Secondary infections by 28 days occurred in 21.9% of patients treated with IL-6 antagonists vs 17.6% of patients treated with usual care or placebo (OR accounting for trial sample sizes, 0.99; 95% CI, 0.85-1.16). CONCLUSIONS AND RELEVANCE In this prospectivemeta-analysis of clinical trials of patients hospitalized for COVID-19, administration of IL-6 antagonists, compared with usual care or placebo, was associated with lower 28-day all-cause mortality